What’s the current market cap for Merck KGaA stock?

Merck KGaA (MRK) has a market cap of €60bn as of June 10, 2026.

What is the P/E ratio for Merck KGaA stock?

The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 23.79 as of June 10, 2026.

Does Merck KGaA stock pay dividends?

Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of June 10, 2026, the dividend rate is €2.2 and the yield is 1.59%. Merck KGaA has a payout ratio of 39.75% on a trailing twelve-month basis.

When is the next Merck KGaA dividend payment date?

The next Merck KGaA (MRK) dividend payment date is unconfirmed.

What is the beta indicator for Merck KGaA?

Merck KGaA (MRK) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Merck KGaA stock | €MRK Share Price

05:30

09:10

12:45

16:25

20:00

About Merck KGaA

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Ticker

€MRK

Sector

Health

Primary listing

XETRA

Employees

59,077

Headquarters

Darmstadt, Germany

Website

www.emdgroup.com

Merck KGaA Metrics

BasicAdvanced

€60bn

23.79

€5.83

0.78

€2.20

1.59%

What the Analysts think about Merck KGaA

Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.

Bulls say / Bears say

Merck KGaA increased its 2026 adjusted operating profit outlook to €5.7–6.1 billion, up from €5.5–6.0 billion, reflecting stronger-than-expected life science demand and the delayed arrival of generics for Mavenclad (Reuters).

Merck KGaA's life science division posted an 8.3% constant-currency revenue rise in Q1 2026, driven by strong demand for drug manufacturing equipment (Reuters).

The €3.9 billion acquisition of SpringWorks Therapeutics boosts Merck KGaA’s pipeline in rare cancer therapies, expanding revenue opportunities beyond its MS business (Reuters).

Merck KGaA expects its 2026 adjusted EBITDA to drop 9.8% to €5.5–6.0 billion, citing the expiration of patent protection for its leading multiple sclerosis drug and negative currency movements (Reuters).

The company will stop including any U.S. Mavenclad sales from May 2026 after generics enter the market, ending a key contributor that produced €1.2 billion in sales last year (Reuters).

First-quarter adjusted EBITDA declined 0.3% year-on-year to €1.53 billion, highlighting underlying margin weakness despite surpassing analyst estimates (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

Merck KGaA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Merck KGaA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy €MRK

€

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Merck KGaA's life science division posted an 8.3% constant-currency revenue rise in Q1 2026, driven by strong demand for drug manufacturing equipment (Reuters).

The €3.9 billion acquisition of SpringWorks Therapeutics boosts Merck KGaA’s pipeline in rare cancer therapies, expanding revenue opportunities beyond its MS business (Reuters).

The company will stop including any U.S. Mavenclad sales from May 2026 after generics enter the market, ending a key contributor that produced €1.2 billion in sales last year (Reuters).

First-quarter adjusted EBITDA declined 0.3% year-on-year to €1.53 billion, highlighting underlying margin weakness despite surpassing analyst estimates (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

About Merck KGaA

Ticker

Primary listing

Employees

Merck KGaA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Merck KGaA

Analyst Ratings

Bulls say / Bears say

Merck KGaA Financial Performance

Income Statement

Merck KGaA Earnings Performance

Earnings per share (EPS)

Buy €MRK

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Merck KGaA/€MRK

About Merck KGaA

Ticker

Primary listing

Employees

Merck KGaA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Merck KGaA

Analyst Ratings

Bulls say / Bears say

Merck KGaA Financial Performance

Income Statement

Merck KGaA Earnings Performance

Earnings per share (EPS)

Buy €MRK

Upcoming events

No upcoming events

What’s the current market cap for Merck KGaA stock?

What is the P/E ratio for Merck KGaA stock?

Does Merck KGaA stock pay dividends?

When is the next Merck KGaA dividend payment date?

What is the beta indicator for Merck KGaA?

Bulls say / Bears say